StageLoan | IPO
About BioNano Genomics
BioNano Genomics offers genome mapping and analysis tools aimed at helping researchers see genome structure to fill in what's missing from sequencing-based data. The company works with institutions in life science, translational research, molecular diagnostics and personalized medicine.
Missing: BioNano Genomics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioNano Genomics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioNano Genomics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioNano Genomics is included in 2 Expert Collections, including Omics.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
BioNano Genomics Patents
BioNano Genomics has filed 39 patents.
The 3 most popular patent topics include:
- Molecular biology
Molecular biology, DNA, Genetics, Biotechnology, DNA sequencing
Molecular biology, DNA, Genetics, Biotechnology, DNA sequencing
Latest BioNano Genomics News
Mar 15, 2023
edicine grants its Next Generation fellowship awards to promising early career professionals in a range of medical genetics and genomics specialties including Biochemical Genetics and Laboratory Genetics and Genomics. Support for this year’s class of Fellows was generously provided by Bionano Genomics, and Sanofi. The ACMG Foundation depends on corporate donations to support these and many other critical programs and thanks all the members of our Corporate Partners Program. “I am very pleased to recognize the recipients of this year’s Next Generation Fellowship Awards, and to acknowledge the support of Bionano Genomics and Sanofi in making these awards possible. These investments in future leaders in medical genetics and genomics are critical to the mission of ACMG and the Foundation,” said Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Foundation. Laboratory Genetics and Genomics Fellowship Award: Amélie Pinard, PhD, University of California San Francisco Dr. Amélie Pinard earned her PhD with highest honors in Human Genetics from Aix-Marseille University in France in 2016. Her doctoral work was titled, “Marfan syndrome and related disorders and identification of novel genes involved in bicuspid aortic valve.” Following her graduation, she continued working on vascular genetics as a postdoctoral researcher in the Medical Genetics Division at the University of Texas Health Science Center in Houston, TX under the supervision of Dr. Dianna Milewicz. Dr. Pinard was the recipient of a postdoctoral fellowship from the American Heart Association allowing her to focus her work on the “Identification and characterization of novel genes for Moyamoya disease” as well as several travel awards to present her results at international meetings including a Brandt Young Scholarship at the 10th Annual Individualizing Medicine Conference. She has published 20 manuscripts in peer-reviewed journals. In July 2022, she started her first year as a Laboratory Genetics and Genomics clinical fellow in the Department of Pathology and Laboratory Medicine at the University of California, San Francisco (UCSF) LGG program. “I am thrilled and very honored to receive this Next Generation Fellowship and Training Award from the ACMG Foundation. I would like to thank UCSF and my program director, Dr. Jessica Van Ziffle for her trust and guidance, as well as my previous and current mentors for advising me to persevere and to always believe in myself to reach my potential, and my co-workers and my family for their unconditional support. As a Next Generation Fellow, I am actively looking forward to being involved in the medical genetics community. As a prospective lab director, I will strive to establish good practices to provide patients and their families with the most adequate results and recommendations,” said Dr. Pinard. Mina Tabrizi, MD, PhD, Oregon Health and Science University Dr. Mina Tabrizi is an Assistant Professor at the Tehran University of Medical Sciences (TUMS) in Iran and is currently a Visiting Scholar at Brown University. She received her MD from the Memorial University of Newfoundland, Canada and her PhD in a joint program from the Cleveland State University and the Cleveland Clinic Lerner Research Institute in Cancer Biology and Regulatory Biology. An accomplished researcher and teacher, Dr. Tabrizi has published more than 50 publications. “My heartfelt gratitude and appreciation to the ACMG Foundation for giving me the Next Generation LGG Award and to the Laboratory Genetics and Genomics team at Oregon Health and Sciences University for their vision and support. It has been my dream to experience a time-tested evidence-based network of laboratories to address the Genetics and Genomics needs of a community and a population,” Dr. Tabrizi said. “Ultimately, standardized systems should be developed, and the workforce should be trained to produce reliable data to be shared worldwide. Genomic variation can contribute to differences in disease susceptibility, drug response and diagnostic accuracy. Through strict adherence to guidelines and standards worldwide, genetic information will most efficiently be utilized toward prevention, diagnosis, prognosis, treatment, follow-up and research to save resources and elevate standards of care and living across socioeconomic levels and populations.” Herodes Guzman, MD, MPH, Children’s Hospital of Philadelphia Herodes Guzman, MD, MPH, completed medical school at the UNC School of Medicine, and a pediatric residency at the Children's Hospital of Philadelphia (CHOP). He is currently a second-year combined fellow in Clinical Genetics, Medical Biochemical Genetics, and Pediatric Endocrinology at CHOP. He is working with Drs. Rebecca Ganetzky and Shana McCormack to better characterize the pathophysiology of mitochondrial diabetes within a cohort of patients with single large scale mitochondrial DNA deletion syndromes, which may have broader practice implications for patients with more common forms of diabetes. Dr. Guzman plans to continue leading clinical research that helps advance the care he provides to his patients with both common and rare metabolic disorders. Dr. Guzman said, “I am honored to have been selected for this ACMG Foundation Next Generation Medical Biochemical Award. It recognizes how interconnected genetics is to endocrinology and all branches of medicine. Through this award, I hope to enhance my understanding of inborn errors of metabolism to facilitate the care I provide to patients with rare disease.” Shira Ziegler, MD, PhD, Johns Hopkins University School of Medicine Shira G. Ziegler, MD, PhD is currently Chief Resident in the Johns Hopkins Department of Genetic Medicine. Dr. Ziegler grew up in Bethesda, MD and spent her summers during high school and college working in the National Human Genome Research Institute (NHGRI). She graduated with highest honors in neuroscience from Oberlin College and then joined the National Institute of Health’s Undiagnosed Diseases Program as their first research fellow. She completed her MD and PhD at Johns Hopkins University School of Medicine. Her graduate research in Dr. Hal Dietz’s laboratory elucidated the mechanisms underlying rare disorders of ectopic and vascular calcification and identified new treatment strategies. She then pursued dual residency training in pediatrics and medical genetics. Dr. Ziegler plans to combine her bench-to-bedside research on rare genetic conditions with clinical care. “I am excited about the opportunity to continue my training in biochemical genetics,” said Dr. Ziegler. About the ACMG Foundation for Genetic and Genomic Medicine The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics and genomics in healthcare. Established in 1992, the ACMG Foundation supports the American College of Medical Genetics and Genomics (ACMG) mission to “translate genes into health.” Through its work, the ACMG Foundation fosters charitable giving, promotes training opportunities to attract future medical geneticists and genetic counselors to the field, shares information about medical genetics and genomics, and sponsors important research. To learn more and support the ACMG Foundation mission to create “Better Health through Genetics” visit www.acmgfoundation.org . Note to editors: To arrange interviews with experts in medical genetics and genomics, contact ACMG Senior Director of Public Relations Kathy Moran, MBA at email@example.com . -end- Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system. Media Contact
BioNano Genomics Frequently Asked Questions (FAQ)
When was BioNano Genomics founded?
BioNano Genomics was founded in 2003.
Where is BioNano Genomics's headquarters?
BioNano Genomics's headquarters is located at 9640 Towne Centre Drive, San Diego.
What is BioNano Genomics's latest funding round?
BioNano Genomics's latest funding round is Loan.
How much did BioNano Genomics raise?
BioNano Genomics raised a total of $119.63M.
Who are the investors of BioNano Genomics?
Investors of BioNano Genomics include Paycheck Protection Program, Innovatus Capital Partners, Aspire Capital, Battelle Ventures, Domain Associates and 16 more.
Who are BioNano Genomics's competitors?
Competitors of BioNano Genomics include BioDiscovery, Fluxion Biosciences, IRX Therapeutics, Nabsys, Hepregen and 11 more.
Compare BioNano Genomics to Competitors
Anthill Technologies, Inc. is pioneering the development and commercialization of a unique proprietary applied chemistry operating system (ACOSï¿½) and a novel high-speed chemical discovery engine based on this operating system to dramatically reduce the time, cost and risk factors associated with discovering and developing chemical compositions, pathways, processes and products for applications in both life science and non-life science markets.
EpigenDx is a genomic and epigenomic research company engaged in disease biomarker discovery and molecular diagnosis. The company aims to provide products related to DNA methylation analysis research. Currently available products include DNA methylation controls and validated DNA methylation assays for human, mouse, and rat. The company also aims to provide products and laboratory services for scientific researchers from academic, government and industrial communities. The company's commitment to quality comes from the company's desire and dedication to provide products and services to the company's customers. As a Biotage AB Certified Laboratory Service provider, EpigenDx has knowledge and expertise in Pyrosequencing and its many applications. CpG methylation and allele quantification analysis are conducted using Biotage's PSQ MD system, while short-read sequence analysis is carried out using Biotage's PSQ ID system.
Natural Science Enterprises Inc. is a research and development group dedicated t the understanding of basic biochemical processes with an emphasis on application for treatments. The company has developed a technology platform, a cationic sub-micron emulsion, allowing for a broad pipeline of products for addressing major conditions as well as orphan diseases.
Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.
NDRI aims to serve scientists with customized human biomaterials for use in studies to understand human disease and to develop drugs and therapies for treatments and cures. NDRI aims to make it easy for researchers to get the human tissues and organs they need, prepared, preserved and shipped precisely according to their specific scientific protocols.
Cira Discovery Sciences, Inc. was founded in 2003 and funded by BioAdvance in 2004 with the mission of discovering biomarker patterns for medical diagnostic products and drug discovery services. The company targets two key application domains, proteomics and flow cytometry, both utilized in the diagnostic and pharmaceutical fields. Cira has developed and patented methods of computational analysis of large, high-dimensionality data sets characteristic of both proteomics and flow cytometry. Advances in these fields are currently hampered by limitations in extracting valuable patentable knowledge from the data. The company ceased operations in 2008 and its intellectual property is being marketed for acquisition.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.